Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Inotiv, Inc.
  6. Company
    NOTV   US45783Q1004

INOTIV, INC.

(NOTV)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
17.64 USD   -2.03%
08/31Inotiv, Inc. to Participate in September Investor Conferences
GL
08/31Inotiv, Inc. to Participate in September Investor Conferences
AQ
08/19Inotiv Files for Potential Follow-On, Secondary Offerings
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Inotiv, Inc.
Inotiv, Inc. is an international contract research company that is focused on providing drug discovery and development services and analytical instruments. The Company focuses on providing drug developers with scientific research and analytical instrumentation. The Company operates through two segments, including Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance and quality control testing. The Research Products segment offers two principal product lines, including analytical products and in vivo sampling products. Analytical products consist of liquid chromatographic and electrochemical instruments with associated accessories. In vivo sampling products consist of the Culex family of automated in vivo sampling and dosing instruments.

Number of employees : 567 people.
Sales per Business
20202021Delta
Services57.1894.6%85.8395.8% +50.12%
Products3.295.4%3.774.2% +14.61%
USD in Million
Sales per region
20202021Delta
United States56.2593%85.2795.2% +51.59%
Pacific Rim2.834.7%2.042.3% -27.81%
Europe1.212%1.802% +48.72%
Other0.040.1%0.360.4% +914.29%
Other North America0.150.2%0.140.2% -3.38%
USD in Million
Managers
Name Title Age Since
Robert Leasure President, Chief Executive Officer & Director 61 2019
Beth A. Taylor Chief Financial Officer & Vice President-Finance 55 2021
Fernanda Beraldi Secretary & General Counsel - -
John E. Sagartz, Dr. Director & Chief Strategy Officer 56 2018
Michael Brunty Senior Director-Operations & Site Optimization - -
John Gregory Beattie COO-Discovery & Development Services 54 -
Mike Garrett Chief Commercial Officer - -
James Harkness COO-Research Models & Services 56 -
Adrian Hardy, Dr. Executive Vice President - -
Brian R Bond, Dr. Senior Director-Cardiorenal Pharmacology - -
Members of the board
Name Title Age Since
Gregory C. Davis, Dr. Chairman 67 2017
Richard Allen Johnson, Dr. Independent Director 75 2012
R. Matthew Neff Independent Director 65 2017
Scott Cragg Independent Director 43 2021
Nigel Brown, Dr. Independent Director 56 2021
John E. Sagartz, Dr. Director & Chief Strategy Officer 56 2018
Robert Leasure President, Chief Executive Officer & Director 61 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 25,593,313 18,938,733 74.0% 0 0.0% 74.0%
Shareholders
NameEquities%
Andrew H. Baker 2,077,422 8.12%
Peter T. Kissinger 1,285,767 5.02%
Ophir Asset Management Pty Ltd. 1,125,473 4.40%
The Vanguard Group, Inc. 825,113 3.22%
P2 Capital Partners LLC 779,463 3.05%
Janus Henderson Investors US LLC 719,275 2.81%
Next Century Growth Investors LLC 695,180 2.72%
John E. Sagartz 681,030 2.66%
Robert Leasure 639,531 2.50%
Kimberly L Sagartz 634,759 2.48%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Inotiv, Inc.